15 results found.

Hematologic Malignancies, Disorder Related to Transplantation, or Clinical Trial using Preparative Regimen

St. Jude Children's Research Hospital - Recruiting N/A to 21 years.
- Umbilical Cord Blood Transplantation In Patients With Hematologic Malignancies Using A Myeloablative Preparative Regimen.
Preparative Regimen

Lymphoma, or Leukemia Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting N/A or older.
- Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Blood and Lymph Node Malignancy.

Hematologic Malignancy Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting N/A to 75 years.
- Hematologic Malignancy Biology Study.

Herpes Zoster Clinical Trial using V212; Placebo

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients With Solid Tumor or Hematologic Malignancy.
V212; Placebo

Hematologic Malignancy, Leukemia, Acute Lymphoblastic Leukemia, A Clinical Trial using Total Body Irradiation (TBI); Donor Lymphocyte Infusion (DLI); Cyclophosphamide (CY); Tacrolimus; Mycophenolate Mofetil (MMF); Hematopoietic Stem Cell Transplant (HSCT)

Thomas Jefferson University - Recruiting 18 years or older.
- A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using Two Related Donors.
Total Body Irradiation (TBI); Donor Lymphocyte Infusion (DLI); Cyclophosphamide (CY); Tacrolimus; Mycophenolate Mofetil (MMF); Hematopoietic Stem Cell Transplant (HSCT)

Non-Hodgkin's Lymphoma, Hodgkin Lymphoma, or Multiple Myeloma Clinical Trial using Nivolumab

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS-936558) in Subjects With Relapsed or Refractory Hematologic Malignancy.
Nivolumab

Cancer, Solid Tumor, or Hematologic Malignancy Clinical Trial

City of Hope Medical Center - Recruiting 65 years or older.
- Delivering the Geriatric Assessment Tool to Older Adults With Cancer Using Computer Survey Methodologies: Testing Feasibility, Reliability, and Validity of Research Electronic Data Capture (REDCap) and Support Screen (Touchscreen) Technologies.

Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia, Acute L Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting N/A or older.
- Relapsed Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation: Screening, Disease Characterization and Natural History.

Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymph Clinical Trial using leukapheresis; allogeneic hematopoietic stem cell transplantation; autologous hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; laboratory biomarker analysis; DNA analysis; RNA analysis; flow cytometry; reverse transcriptase-polymerase chain reaction; nucleic acid sequencing; protein expression analysis

Fred Hutchinson Cancer Research Center - Recruiting N/A to 75 years.
- Human Immunodeficiency Virus (HIV)-Specific Immune Reconstitution After Hematopoietic Cell Transplant for Treatment of Hematologic Malignancy in Patients Infected With HIV.
leukapheresis; allogeneic hematopoietic stem cell transplantation; autologous hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; laboratory biomarker analysis; DNA analysis; RNA analysis; flow cytometry; reverse transcriptase-polymerase chain reaction; nucleic acid sequencing; protein expression analysis

Hematologic Malignancy Clinical Trial using Fludarabine IV- Busulfan IV (Busilvexr) - Anti-thymocyte globulines (Thymoglobuliner)

Nantes University Hospital - Recruiting 12 Months to 18 years.
- Phase 2 Study of a Reduced-toxicity Myeloablative Conditionning Regimen Using Fludarabine and Full Doses of iv Busulfan in Pediatric Patients Not Eligible for Standard Myeloablative Conditioning Regimens.
Fludarabine IV- Busulfan IV (Busilvexr) - Anti-thymocyte globulines (Thymoglobuliner)

Invasive Fungal Infection Clinical Trial using voriconazole

Asan Medical Center - Recruiting 15 years or older.
- The Correlation of Voriconazole Trough Plasma Levels With Genetic Polymorphism, Efficacy, and Safety Outcomes in Hematologic Malignancy Patients With Invasive Pulmonary Aspergillosis.
voriconazole

Hematologic Malignancy Requiring Allogeneic Stem-cell Transplanta Clinical Trial using Maraviroc 300 mg

Abramson Cancer Center of the University of Pennsylvania - Recruiting 18 years or older.
- A Phase II Study to Assess the Efficacy of Maraviroc, a CCR5-Antagonist in Prophylaxis of Graft-Versus-Host Disease in Patients With Hematologic Malignancies Undergoing Reduced-Intensity Allogeneic Stem-Cell Transplantation From Unrelated Donors.
Maraviroc 300 mg

Hematological Malignancy, or Bone Marrow Failure Syndrome Clinical Trial using Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders

University of British Columbia - Recruiting N/A or older.
- Umbilical Cord Blood Transplantation as Treatment of Adult Patients With Hematologic Disorders.
Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders

Hematologic Malignancy Clinical Trial using Total Body Irradiation (TBI); Donor Lymphocyte Infusion (DLI); Cyclophosphamide; Stem Cell Infusion

Thomas Jefferson University - Recruiting 18 years or older.
- A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies From One Versus Two HLA Partially-Matched Related Donors.
Total Body Irradiation (TBI); Donor Lymphocyte Infusion (DLI); Cyclophosphamide; Stem Cell Infusion

Cancer, Solid Tumor, or Hematologic Malignancy Clinical Trial

Community Cancer Care - Recruiting 18 years or older.
- Home-Based Symptom Monitoring: Its Impact on Cancer Care Team Behaviors and Patient Outcomes.